Anaplastic large cell lymphoma (ALCL) is a highly proliferative neoplasm that frequently carries the t(2;5)(p23;q35) and aberrantly expresses NPM-ALK. Previously, NPM-ALK has been shown to activate the PI3K/Akt pathway. As the cyclin-dependent kinase (CDK) inhibitor p27
that activated Akt (pAkt) phosphorylates p27 resulting in increased p27 proteolysis and cell cycle progression. Here we demonstrate that inhibition of pAkt activity in ALCL decreases p27 phosphorylation and degradation, resulting in increased p27 levels and cell cycle arrest. Using immunohistochemistry, pAkt was detected in 24/42 (57%) ALCL tumors including 8/18 (44%) ALK-positive and 16/24 (67%) ALK-negative, and was inversely correlated with p27 levels. The mean percentage of p27-positive tumor cells was 5% in the pAkt-positive group compared with 26% in the pAkt-negative group (p = 0.0076). These findings implicates that Akt activation promotes cell cycle progression through inactivation of p27 in ALCL.
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INTRODUCTION
The biologic significance of the serine/theronine kinase Akt in lymphomagenesis has been recently established in a mouse model. 1 In that study, forced Akt expression in hematopoietic stem cells of Eµ-Myc mice markedly accelerated lymphomagenesis and the murine lymphomas were characterized by rapid cell proliferation and low apoptotic rate. Anaplastic large cell lymphoma (ALCL) is an aggressive form of malignant lymphoma of T/null immunophenotype. 2 A subset of ALCL tumors carry variant chromosomal aberrations involving the ALK (anaplastic lymphoma kinase) gene on chromosome 2p23. 3 The most common of these aberrations is the t (2;5)(p23;q35) , which results in the expression of the chimeric protein NPM (nucleophosmin)-ALK. 4 Recent studies have shown that, at least in part, NPM-ALK mediates oncogenesis through phosphorylation/activation of Akt (pAkt). 5, 6 We have previously shown that the cyclin-dependent kinase (CDK) inhibitor p27, a negative-regulator of G 1 -S cell cycle transition, 7, 8 is absent in the majority of ALCL tumors, 9 implying an important role for p27 in the pathogenesis of ALCL. Recently, it was demonstrated in breast cancer that pAkt is capable of phosphorylating p27 causing its cytoplasmic retention and subsequent degradation through the ubiquitin-proteasome pathway. [10] [11] [12] We hypothesized that phosphorylation of p27 is mediated by pAkt in ALCL. In this report, we have demonstrated that inhibition of pAkt significantly decreases threonine p27 phosphorylation and increases total p27 levels, resulting in cell cycle arrest. We have also shown that Akt is activated in a substantial subset of ALCL tumors, and that Akt activation is associated with significantly lower levels of p27 and higher 
MATERIALS AND METHODS

Cell lines and Reagents
Two ALK-positive ALCL cell lines, Karpas 299 and SU-DHL1, were used. The cell lines were maintained at 37°C in RPMI-1640 medium supplemented with 10% fetal calf serum in a humidified atmosphere containing 5% CO 2 . Akt inhibitor (Akt-II) was purchased from Calbiochem (San Diego, CA). Two proteasome inhibitors were also used, LLnL (Sigma, St. Louis, MO) and MG132 (Calbiochem).
Western Blot analysis
Western blot analysis was performed using standard methods. 9 Subcellular fractionation was performed using the NE-PERTM kit (Pierce, Rockford, IL). The antibodies used were Akt, pAkt (both from Cell Signaling Technology, Beverly, MA), p27
(BD Biosciences Pharmingen, San Diego, CA), Rb (Dakocytomation, Carpinteria, CA), phosphorylated threonine (Santa Cruz Biotechnology, Santa Cruz, CA), and -actin (Sigma).
Immunoprecipitation
Cell lysates were incubated with anti-p27 antibody overnight at 4°C, and subsequently with protein A/G sepharose (Santa Cruz) for 4 hours at 4°C. Four washes with cold PBS and one wash with lysis buffer were then performed, followed by boiling in SDS-PAGE loading buffer for 5 minutes. Immunoblotting was then performed using anti-p27 antibody or anti-phosphorylated threonine (pThr) antibodies.
Cell cycle analysis
Cell cycle analysis was performed using a bromodeoxyuridine ( Full tissue sections, a tissue microarray, and an immunohistochemical method were used as previously described. 13, 14 The monoclonal antibodies were specific for pAkt (Ser 473 , Cell Signaling Technology), p27 (Dakocytomation) and Ki-67 (MIB-1, Immunotech, Westbrook, ME).
Statistical Analysis
Chi-square and Fisher's exact tests were used to compare pAkt expression with various clinicopathological parameters. The Mann-Whitney U test was chosen for nonparametric correlation of pAkt expression with the percentage of p27-positive tumor cells and the proliferation index (PI). Progression-free survival (PFS) 9 was calculated separately for ALK-positive and ALK-negative ALCL groups using the Kaplan-Meier method and logrank test. Statistical calculations were performed using StatView (Abacus Concepts, Inc.; Berkeley, CA).
RESULTS AND DISCUSSION
ALCL is a high-grade lymphoma type that frequently lacks p27 expression. 9 In this study, we hypothesized that Akt mediates downregulation of p27 in ALCL. We tested the Akt-II inhibitor used in the present study and found that it substantially decreases Akt kinase activity (data not shown). Western blot analysis revealed a concentration- Treatment of ALCL cells with two 26S proteasome inhibitors, LLnL and MG132, resulted in increased total p27 levels (Figure 1d ), suggesting that p27 is primarily regulated through ubiquitin-proteasome-mediated degradation in our in vitro system, as shown in other cell types. 15 Treatment of ALCL cells with Akt-II in the presence of the proteasome inhibitors at a concentration known to completely inhibit proteasome-mediated protein degradation resulted in no additional increase of total p27 protein level (Figure 1d ).
These results demonstrate that in ALCL Akt inhibition causes cell cycle arrest that can be attributed to a significant decrease of threonine-phosphorylation and inactivation of p27.
Subcellular fractionation showed that Akt and pAkt are predominantly localized in the cytoplasm in Karpas 22 cells ( Figure 2a ). Weak nuclear localization of pAkt was also These findings indicate that the high PI reported in ALCL 14 can be partially explained by constitutive activation of Akt leading to threonine phosphorylation at Thr157 or Thr198 17 and increased degradation of p27. Low p27 levels, in turn, lead to increased phosphorylation and inactivation of Rb resulting in release of E2F transcription factors and cell cycle progression. This is further corroborated by the frequent loss of Rb expression due to deletion of rb locus recently reported in ALCL.
18
Of note, we have shown that presence of Rb, that is frequently phosphorylated, is associated with low p27 levels and adverse clinical outcome in these tumors. 18 Using an in vitro system, a recent study has shown that forced expression of NPM-ALK into the murine pro-B cells Ba/F3 caused downregulation of p27 via pAkt/FOXO3a. 19 Using ALK-positive ALCL cell lines, we demonstrate here that pAkt is involved in p27 downregulation. However, the absence of a significant correlation between pAkt and ALK status in ALCL tumors indicates that other mechanisms may play a role in pAkt-mediated downregulation of p27 in vivo.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Densitometry of the immunoblot bands showed a substantial decrease in the threonine phopsphorylated p27/IgG ratio that was associated with increased total p27/IgG ratio. were used at a concentration of 35µM each, and were previously shown to adequately block proteasome activity (data not shown). Pre-treatment of ALCL cells with proteasome inhibitors for 4 h followed by treatment of cells with both proteasome inhibitors and Akt-II for 12 h resulted in no additional increase of total p27 levels (lanes 3 and 5) that demonstrates complete blockade of proteasome-mediated degradation.
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